Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-Human Study of GLPG2222
NCT02662452Phase 1Completed
- Sponsor
- Galapagos NV
- Start
- Jan 2016
- Primary completion
- Apr 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of galicaftor in cystic fibrosis (CF) (4 arms), sponsored by Galapagos NV. Primary endpoints: Number of subjects with adverse events, Number of subjects with abnormal laboratory parameters and 4 more. Started Jan 2016; status: completed.
02
Drugs
galicaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT02662452.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02662452.